# Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

> **NCT03593213** · PHASE3 · TERMINATED · sponsor: **AbbVie** · enrollment: 587 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Cariprazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03593213
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-30
- **Primary completion:** 2021-02-11
- **Final completion:** 2021-02-11
- **Target enrollment:** 587 (ACTUAL)
- **Why stopped:** FDA Released Allergan from this post marketing requirement
- **Last updated:** 2022-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03593213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03593213, "Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03593213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*